<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639858</url>
  </required_header>
  <id_info>
    <org_study_id>DOCH&amp;N201</org_study_id>
    <nct_id>NCT02639858</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC</brief_title>
  <official_title>A Phase II Study to Evaluate the Efficacy and Safety of Docetaxel-PM in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samyang Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samyang Biopharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II study to evaluate the efficacy and safety of Docetaxel-PM in recurrent or&#xD;
      metastatic head and neck squamous cell carcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate as assessed by RECIST v1.1</measure>
    <time_frame>2 years</time_frame>
    <description>Response is confirmed at least 4 weeks later. Assessment: every 6 weeks (treatment period), every 2 months (follow-up period)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment: every 2 months (follow-up period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>DCR is defined as the percentage of patients who have achieved complete response, partial response and stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment: every 2 months (follow-up period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of hypersensitivity reaction to Docetaxel-PM</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Docetaxel-PM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel-PM 75mg/m2 IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel-PM</intervention_name>
    <description>Docetaxel PM 75mg/m2 IV infusion</description>
    <arm_group_label>Docetaxel-PM</arm_group_label>
    <other_name>Nanoxel M</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who were histologically or cytologically diagnosed as having oral cavity,&#xD;
             oropharynx, hypopharynx, or larynx squamous cell carcinoma with recurrent and&#xD;
             metastatic evidence and who cannot be treated by salvage surgery or radiotherapy&#xD;
&#xD;
          2. Time of disease progression, regardless of whether that treatment or after&#xD;
             platinum-based therapy&#xD;
&#xD;
             ①Patients who have disease progression after concurrent chemoradiotherapy of curative&#xD;
             purpose (including induction chemotherapy) including a platinum-based (cisplatin or&#xD;
             carboplatin) chemotherapy&#xD;
&#xD;
             ② Patients who have disease progression after primary or secondary treatment of&#xD;
             palliative purpose including a platinum-based (cisplatin or carboplatin) chemotherapy&#xD;
&#xD;
          3. Patients who aged 20 years or older and under 79 years old&#xD;
&#xD;
          4. Patients whose Eastern Cooperative Oncology Group (ECOG) performance scores are 0-2&#xD;
&#xD;
          5. Patients who have one measurable lesion at least by RECIST criteria 1.1&#xD;
&#xD;
          6. Patients who show adequate function of organ:&#xD;
&#xD;
               -  bone marrow: Absolute Neutrophil count (ANC) ≥ 1,500/μL, Platelet count ≥&#xD;
                  100,000/μ, Hb≥ 9.0 g/dl (allowed blood transfusion)&#xD;
&#xD;
               -  Liver: ① with no evidence of liver metastasis; Total bilirubin ≤ 1.5mg/dl,&#xD;
                  alkaline phosphatase (ALP), aspartate transaminase (AST), alanine transaminase&#xD;
                  (ALT) ≤ 2.0 X upper limit of normal (ULN)&#xD;
&#xD;
                  ② with liver metastasis; bilirubin ≤ 3.0 X ULN, aspartate transaminase (AST),&#xD;
                  alanine transaminase (ALT) ≤ 5.0 X ULN&#xD;
&#xD;
               -  Kidney: creatinine ≤ 1.5 X ULN&#xD;
&#xD;
          7. Patients who have signed written consent forms prior to participation in the clinical&#xD;
             trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have Primary tumor of nasopharynx&#xD;
&#xD;
          2. Patients who have received treatment prior regimen of three or more drugs&#xD;
&#xD;
          3. Patients who have Primary malignant tumors of other sites (except if; early cervical&#xD;
             cancer, skin basal cell cancer received appropriate treatment, Malignant tumor without&#xD;
             recurrent state treated five years previously)&#xD;
&#xD;
          4. Previous radiotherapy is allowed, patients who should be completed radiotherapy before&#xD;
             4 weeks prior to the initial administration of the investigational product&#xD;
&#xD;
          5. Patients who have received a major surgery within 4 weeks prior to the initial&#xD;
             administration of the investigational product or patients who does not recover after&#xD;
             major surgery&#xD;
&#xD;
          6. Patients who have severe diseases or medical condition as follows&#xD;
&#xD;
               -  Congestive heart failure(NYHA class III or IV)&#xD;
&#xD;
               -  Unstable angina, cardiac infarction within 6 months&#xD;
&#xD;
               -  Second-degree atrioventricular (AV) block or more, clinically cardiac arrhythmia&#xD;
                  that needs drug therapy&#xD;
&#xD;
               -  Uncontrollable Hypertension&#xD;
&#xD;
               -  Hepatic cirrhosis (≥ Child class B)&#xD;
&#xD;
               -  Interstitial lung disease&#xD;
&#xD;
               -  Mental disorder not to comply with the protocol&#xD;
&#xD;
               -  Uncontrolled diabetes&#xD;
&#xD;
               -  Uncontrolled ascites or pulmonary edema&#xD;
&#xD;
               -  Active infection&#xD;
&#xD;
          7. Pregnant or lactating women&#xD;
&#xD;
          8. Patients considered inappropriate to participating the study by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samyang Biopharmaceuticals</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miryung Jin</last_name>
      <phone>+82-2-740-7289</phone>
      <email>miryung.jin@samyang.com</email>
    </contact>
    <investigator>
      <last_name>Sung Bae Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2015</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

